Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration.
Methods
Fourteen HIV patients for whom TDF dose was adjusted (1 tablet/48 h) because of estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2, and/or due to a tenofovir trough concentration >90 ng/ml between 2006 and 2013 were selected. The eGFR was measured at baseline and 3, 6 and 12 months after TDF dose adjustment.
Results
A 50% TDF dose reduction resulted in a significant increase of the eGFR 3 months after dose adjustment (61.1 versus 72.8 ml/min/1.73 m2; P=0.003). Concomitantly, tenofovir trough concentration decreased from 175 to 66 ng/ml (P=0.009). Antiviral efficacy was maintained in all patients.
Conclusions
TDF dose adjustment combined with therapeutic drug monitoring may be useful especially in patients at risk of kidney dysfunction.
BarriosA., García-BenayasT., González-LahozJ., SorianoV.Tenofovir-related nephrotoxicity in HIV-infected patients.AIDS2004; 18: 960–963.
4.
Fernandez-FernandezB., Montoya-FerrerA., SanzA.B.Tenofovir nephrotoxicity: 2011 update.Aids Res Treat2011; 2011: 354908.
5.
ScherzerR., EstrellaM., LiY.Association of tenofovir exposure with kidney disease risk in HIV infection.AIDS2012; 26: 867–875.
6.
Rodríguez-NóvoaS., LabargaP., D'avolioA.Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.AIDS2010; 24: 1064–1066.
7.
EzingaM., WetzelsJ.F.M., BoschM.E.W., van der VenA.J.A.M., BurgerD.M.Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.Antivir Ther2014; 19: 765–771.
8.
GagnieuM-C, BarkilM.E., LivrozetJ-MPopulation pharmacokinetics of tenofovir in AIDS patients.J Clin Pharmacol2008; 48: 1282–1288.
9.
JullienV., TréluyerJ-M, ReyE.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Antimicrob Agents Chemother2005; 49: 3361–3366.
10.
CalcagnoA., Gonzalez de RequenaD., SimieleM.Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.Antimicrob Agents Chemother2013; 57: 1840–1843.
11.
Poizot-MartinI., SolasC., AllemandJ.Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration.J Acquir Immune Defic Syndr2013; 62: 375–380.
12.
MorlatP.[French recommendations for the clinical management of HIV patients]. Paris, FRANCE: Ministère des affaires sociales et de la Santé. Conseil national du Sida. Agence nationale de recherches sur le sida et les hépatites virales. Rapport 2013. French. (Accessed 4 November 2016.) Available from http://social-sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.
13.
PuglieseP., CuzinL., CabiéA.A large French prospective cohort of HIV-infected patients: the Nadis Cohort.HIV Med2009; 10: 504–511.
14.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine.Nephron1976; 16: 31–41.
15.
LeveyA.S., BoschJ.P., LewisJ.B., GreeneT., RogersN., RothD.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med1999; 130: 461–470.
16.
GoolsbyM.J.National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification.J Am Acad Nurse Pract2002; 14: 238–242.
MillsA., CrofootG., McDonaldC.Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized Phase 2 study.J Acquir Immune Defic Syndr2015; 69: 439–445.
19.
SaxP.E., ZolopaA., BrarI.Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized Phase 2 study.J Acquir Immune Defic Syndr2014; 67: 52–58.
20.
MikulaJ.M., ManionM.M., MaldarelliF.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy.Antivir Ther2016; 21: 553–558.
21.
PostF.A., TebasP., ClarkeA.Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label Phase 3 study.J Acquir Immune Defic Syndr2017; 74: 180–184.
